Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia

NCT07791498 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT07791498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07791498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 19, 2027
Completion date
September 1, 2029
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom's macroglobulinemia